Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Marz, W; Schmidt, N; Haack, IA; Dressel, A; Grammer, TB; Kleber, ME; Baessler, A; Beil, FU; Gouni-Berthold, I; Julius, U; Kassner, U; Katzmann, JL; Klose, G; Konig, C; Koenig, W; Koschker, AC; Laufs, U; Merkel, M; Otte, B; Parhofer, KG; Hengstenberg, W; Schunkert, H; Stach-Jablonski, K; Steinhagen-Thiessen, E; Olivier, CB; Hahmann, H; Krzossok, S; Vogt, A; Muller-Wieland, D; Schatz, U.
The German CaRe high registry for familial hypercholesterolemia- Sex differences, treatment strategies, and target value attainment
ATHEROSCLER PLUS. 2023; 53: 6-15.
Doi: 10.1016/j.athplu.2023.06.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- März Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background and aims: Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low -density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines.Methods: We evaluated consolidated datasets from 1501 FH patients diagnosed clinically and seen either by lipid specialists or general practitioners and internists. We conducted a questionnaire survey of both the recruiting physicians and patients.Results: Among the 1501 patients, 86% regularly received lipid-lowering drugs. LDL-C goals were ach-ieved by 26% and 10% of patients with atherosclerotic cardiovascular disease (ASCVD) according to the 2016 and 2019 ESC/EAS dyslipidemia guidelines, respectively. High intensity lipid-lowering was administered more often in men than in women, in patients with ASCVD, at higher LDL-C and in patients with a genetic diagnosis of FH.Conclusions: FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals of the 2019 ESC/EAS dyslipidemia guidelines remains challenging if pre-treatment LDL-C is very high.& COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Find related publications in this database (Keywords)
- Familial hypercholesterolemia
- Cascade screening
- Patient registry
- Cardiovascular risk
- Treatment
- Adherence
- Low-density lipoproteins